Skip to main content
. 2021 Sep 10;88(6):973–983. doi: 10.1007/s00280-021-04351-w

Table 2.

Steady state Ruxolitinib trough serum concentrations of all samples across all individuals

Daily dose (mg) No. of samples (no. of excluded samples < LLOQ) Median (ng/mL) IQR (ng/mL) Range (ng/mL)
All 174 (8) 31.4 31.95 2.2–229
20 120 (2) 40.5 33.9 2.7–229
 > 20–40 3 (1) 25.1 12.1 4.3–28.5
5–< 20 51 (5)a 17.5 10.9 2.2–155

LLOQ lower limit of quantification (2 ng/mL)

aAll trough serum concentrations at 5 mg daily were ≤ 2.17 ng/mL (3 of 4 samples < LLOQ)